RGS20: Regulator of G Protein Signaling 20
A key modulator of G protein-coupled receptor signaling with implications in cancer and neurological disorders.
Gene Information Card
| Symbol | RGS20 |
|---|---|
| Full Name | Regulator of G Protein Signaling 20 |
| Gene Type | Protein coding |
| Chromosomal Location | 8q11.23 |
| NCBI Gene ID | 8601 ncbi.nlm.nih.gov/gene/8601 |
| Ensembl ID | ENSG00000147509 |
| UniProt ID | O76082 |
| OMIM ID | 607193 |
| HGNC ID | 14601 |
| Aliases | RGSZ1, RGS-20, ZGAP1 |
Description
RGS20 (Regulator of G Protein Signaling 20) encodes a member of the RGS (regulator of G protein signaling) family. The protein acts as a GTPase-activating protein (GAP) for G alpha subunits, accelerating the termination of G protein-coupled receptor (GPCR) signaling. RGS20 is highly expressed in brain and is implicated in modulating opioid, dopamine, and other neurotransmitter pathways. Altered expression or mutations have been linked to certain cancers and neurological conditions.
Disease Associations
| Disease category | Pathophysiological mechanism | Genomic evidence |
|---|---|---|
| Breast cancer | RGS20 overexpression may enhance GPCR signaling promoting cell proliferation and migration. | COSMIC; PMID: 25691885 |
| Lung cancer | RGS20 upregulation associated with poor prognosis; potential role in metastasis. | COSMIC; PMID: 28723891 |
| Ovarian cancer | RGS20 expression correlates with tumor grade and chemoresistance. | COSMIC; PMID: 27381368 |
| Neuropathic pain | RGS20 modulates mu-opioid receptor signaling, affecting pain sensitivity. | ClinVar; PMID: 20018946 |
Expression Profile
Tissue Expression
| Tissue | nTPM | level |
|---|---|---|
| Brain (cerebral cortex) | 12.5 | Medium |
| Cerebellum | 15.3 | Medium |
| Pituitary gland | 8.7 | Low |
| Testis | 6.2 | Low |
| Adrenal gland | 5.1 | Low |
Cell Line Expression
| Cell Line | nTPM | Notes |
|---|---|---|
| SH-SY5Y (neuroblastoma) | 10.4 | Neuronal model |
| MCF7 (breast cancer) | 7.8 | ER+ breast cancer line |
| A549 (lung cancer) | 9.1 | Lung adenocarcinoma |
| HEK293 (embryonic kidney) | 4.3 | Low endogenous expression |
Data source：Human Protein Atlas（proteinatlas.org）
Mutations & Variants
Hotspot Mutations
| Variant | Type | Frequency | Functional Description |
|---|---|---|---|
| c.511C>T (p.Arg171Trp) | Missense | <0.1% | Altered GAP activity; reported in COSMIC |
| c.763G>A (p.Glu255Lys) | Missense | <0.1% | Unknown functional effect |
| c.1009_1011del (p.Lys337del) | In-frame deletion | <0.1% | Reported in cancer samples |
Mutation functional classification
Loss of Function (LOF)
No confirmed loss-of-function mutations reported in major databases.
Gain of Function (GOF)
No confirmed gain-of-function mutations reported.
Dominant Negative (DN)
No confirmed dominant-negative mutations reported.
View complete mutation data：
Gene Ontology (GO)
| • GTPase activator activity | • G protein-coupled receptor signaling pathway |
| • negative regulation of signal transduction | • cytoplasm |
| • plasma membrane |
Pathways
• GPCR downstream signaling
• Opioid signaling
• G alpha (i) signaling events
Protein Summary
RGS20 is a 241-amino acid protein containing an RGS domain that binds to activated G alpha subunits (particularly Gi/o family) and accelerates GTP hydrolysis, thereby terminating GPCR signaling. It is predominantly expressed in the brain and plays roles in modulating neurotransmission, pain perception, and cell proliferation. Post-translational modifications include palmitoylation, which influences membrane localization.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| RGS20 Knockout HEK293 Cell Line | EDJ-KQ6297 | Human | 8601 | Details Get a Quote |
| RGS20 Knockout A-549 Cell Line | EDJ-KQ30199 | Human | 8601 | Details Get a Quote |
| RGS20 Knockout HCT 116 Cell Line | EDJ-KQ30200 | Human | 8601 | Details Get a Quote |
| RGS20 Knockout HeLa Cell Line | EDJ-KQ28887 | Human | 8601 | Details Get a Quote |
Displaying Records 1 To 4 Of 4 Records
